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ndothelin and
he Systemic Circulation
Therapeutic Target Worth Revisiting?*
ewis J. Rubin, MD
a Jolla, California
ndothelin (ET)-1, one of the most potent endogenous
asoconstrictors and promoters of vascular growth, is pro-
uced by vascular endothelial cells in response to a variety of
timuli (1,2). The development of ET receptor antagonists
3) facilitated the exploration of the pathophysiological role
f ET-1 in a variety of diseases in which ET-1 expression is
ncreased, including systemic hypertension (4), congestive
eart failure (5), Raynaud’s phenomenon and digital ulcers
n scleroderma (6), pulmonary arterial hypertension (7), and
diopathic pulmonary fibrosis (8). Despite large-scale clini-
al trials in these conditions, ET receptor antagonists have
een demonstrated to have convincing clinical effects only in
ulmonary arterial hypertension, the sole condition for
hich both the dual ET-A and ET-B receptor antagonist
osentan and the more selective ET-A receptor antagonist
mbrisentan have received approval by the Food and Drug
dministration. In this issue of the Journal, Belaidi et al. (9)
rovide evidence that ET-1 may play a more significant role
n the systemic circulation under certain conditions, specif-
cally intermittent hypoxia in the background of a predis-
osition for systemic hypertension, and suggest that the
linical scenario that they sought to mimic in their studies—
bstructive sleep apnea (OSA)—may benefit from therapy
ith ET receptor antagonists.
See page 1309
Belaidi et al. (9) exposed control and spontaneously
ypertensive rats to intermittent hypoxia designed to mimic
he frequent intervals of apnea that are experienced by
ndividuals with severe, uncontrolled OSA, and found that
he spontaneously hypertensive rats, but not control rats,
anifested greater increases in blood pressure and coronary
asoreactivity along with increased expression of ET-1 and
ypoxia-inducible transcription factor (HIF)-1. In addition,
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From the University of California, San Diego, La Jolla, California. Dr. Rubin has
erved as a consultant and investigator for Actelion, Gilead, and Pfizer.he administration of bosentan blocked these augmented
ystemic vascular responses. They suggest that HIF-1 me-
iates the increased ET-1 expression in their model.
OSA is a common disorder that has been increasingly
ecognized as a significant contributing factor to cardiovas-
ular morbidity and mortality, including both systemic
ypertension and heart failure (10,11). Although lifestyle
hanges, such as weight loss and avoidance of alcohol and
ther sedatives, are effective in some patients with OSA,
hese are not always contributory factors, and other active
easures for management are often needed. Continuous
ositive airway pressure applied at night is an effective, albeit
umbersome, therapy for OSA that, when adjusted to the
atient’s individual requirements and used consistently,
ffectively reverses nocturnal hypoxemia and may reduce the
omorbid cardiovascular events. Technological advances in
his field have improved the diagnostic approach to OSA as
ell as patient comfort and compliance with the hardware
sed for its treatment. It is unlikely, therefore, that, given
he expense and toxicities of ET receptor antagonists, these
gents will have much advantage over current therapy for
SA, although studies in OSA patients who have persistent
ardiovascular comorbidities despite continuous positive
irway pressure therapy may be of potential interest. Per-
aps more worthy of study are other conditions in which
ntermittent hypoxia coexists with systemic vascular disease,
otably the aging population with smoking-related chronic
bstructive pulmonary disease and coexistent systemic hyper-
ension or arteriosclerotic heart disease: while an extrapolation
rom the studies of Belaidi et al. (9) to this clinical condition is
qually fraught with limitations, the medical need is consider-
ble and the rationale is strengthened by their findings.
The experiments presented by Belaidi et al. (9) provide
vidence that HIF-1 and ET-1 interact in experimental
onditions that are related, but not identical, to human
isease. Whether this observation will translate to a new
herapeutic target for ET receptor antagonists is unclear,
ut it at least provides a rationale for exploring the effects of
hese drugs in relevant populations for which novel ap-
roaches to therapy are needed.
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